Home  | News

28.01.2026

Teaser image to Matthias Nießner Co-Founds AI Startup Synthesia

Matthias Nießner Co-Founds AI Startup Synthesia

Interactive AI Avatars Reshape Corporate Training

The London-based AI company Synthesia, co-founded by MCML PI Matthias Nießner, has raised an additional $200 million, bringing its valuation to $4 billion. Synthesia is one of Europe’s most valuable AI startups and a pioneer in AI-generated video avatars for corporate training and communication.

With the new funding, Synthesia aims to expand beyond static training videos toward interactive AI avatars that can simulate conversations, test employees’ knowledge, and provide personalized feedback. These virtual trainers are designed to support onboarding, sales training, and internal education, enabled by recent advances in generative AI and large language models.

#media #research #niessner
Subscribe to RSS News feed

Related

Link to Cracks in the foundations of cosmology

30.01.2026

Cracks in the Foundations of Cosmology

Daniel Grün examines cosmological tensions that challenge the Standard Model and may point toward new physics.

Link to How Machines Can Discover Hidden Rules Without Supervision

29.01.2026

How Machines Can Discover Hidden Rules Without Supervision

ICLR 2025 research shows how self-supervised learning uncovers hidden system dynamics from unlabeled, high-dimensional data.

Link to Fabian Theis Featured in FOCUS Online at DLD 2026

28.01.2026

Fabian Theis Featured in FOCUS Online at DLD 2026

Fabian Theis was featured in FOCUS Online at DLD 2026, discussing how AI can support doctors and improve diagnosis and access to healthcare.

Link to Daniel Rückert Speaks at DLD Munich 2026

27.01.2026

Daniel Rückert Speaks at DLD Munich 2026

Daniel Rückert spoke at DLD Munich 2026 in the session "AI and the Future of Medicine: From Sci-Fi to Your Doctor’s Office."

Link to Fabian Theis Speaks at DLD Munich 2026

27.01.2026

Fabian Theis Speaks at DLD Munich 2026

Fabian Theis spoke at DLD Munich 2026 with his talk “From Models to Medicines” and joined a panel "From the Cell to Clinical Application".

Back to Top